JPH08511245A - 薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体 - Google Patents
薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体Info
- Publication number
- JPH08511245A JPH08511245A JP6525716A JP52571694A JPH08511245A JP H08511245 A JPH08511245 A JP H08511245A JP 6525716 A JP6525716 A JP 6525716A JP 52571694 A JP52571694 A JP 52571694A JP H08511245 A JPH08511245 A JP H08511245A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lipid
- composition according
- drug
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S428/00—Stock material or miscellaneous articles
- Y10S428/922—Static electricity metal bleed-off metallic stock
- Y10S428/9335—Product by special process
- Y10S428/937—Sprayed metal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.重量ベースで測定したとき、平均直径が約10〜250nmである複数の非細胞 性脂質粒子の、医薬として許容される担体溶液中のナノエマルションを含有する 医薬投与用医薬組成物であって;前記の各脂質粒子が、バルクで測定したとき、 25℃で固相もしくは液晶相である脂質で構成された脂質コアを含有し、前記脂質 コアが、リン脂質を含有する少なくとも一つの表面層によって囲まれている医薬 組成物。 2.前記脂質粒子の平均粒径が、重量ベースで測定したとき、約20〜180nmの 範囲内にある請求の範囲1記載の組成物。 3.前記脂質粒子の少なくとも99%の粒径が、重量ベースで測定したとき、約 50〜150nmの範囲内にある請求の範囲2記載の組成物。 4.脂質コアが脂肪酸エステルを含有している請求の範囲2記載の医薬組成物 。 5.脂質コアが、バルクで測定したとき、固相から流体相への転移温度が37℃ より低い請求の範囲4記載の医薬組成物。 6.脂質コアが、バルクで測定したとき、固相から流体相への転移温度が37℃ より高い請求の範囲4記載の医薬組成物。 7.脂質コアがトリグリセリドを含有する請求の範囲4記載の医薬組成物。 8.前記トリグリセリドがC10〜C18の脂肪酸部分を含有している請求項7記 載の医薬組成物。 9.前記トリグリセリドが完全に飽和されている請求の範囲7記載の医薬組成 物。 10.前記トリグリセリドが、トリカプリン、トリラウリン、トリ ミリスチン、トリパルミチンおよびトリステアリンからなる群から選択される請 求の範囲7記載の医薬組成物。 11.リン脂質:全脂質のモル比が0.1:1〜0.5:1の範囲内にある請求の範囲 7記載の組成物。 12.リン脂質:トリグリセリドの重量比が0.5:1〜1.5:1の範囲内にある請 求の範囲7記載の組成物。 13.前記リン脂質がホスファチジルコリンを含有している請求の範囲4記載の 医薬組成物。 14.前記ホスファチジルコリンが卵PCである請求の範囲13記載の医薬組成物。 15.前記ホスファチジルコリンが25℃より低い転移温度を有する請求の範囲13 記載の医薬組成物。 16.前記ホスファチジルコリンが飽和されている請求の範囲13記載の医薬組成 物。 17.前記脂質粒子がコレステロールまたはコレステリルエステルを含有してい る請求の範囲1の医薬組成物。 18.前記脂質粒子が医薬を含有している請求の範囲1記載の医薬組成物。 19.前記医薬が脂質に溶解性の医薬である請求の範囲18記載の医薬組成物。 20.前記医薬が水溶性医薬である請求の範囲18記載の医薬組成物。 21.前記医薬が、非ステロイドの抗炎症化合物類、抗新生物化合物類、抗生物 質類、抗けいれん剤類、抗てんかん剤類、抗真菌剤類、抗ウイルス剤類、グリコ サミノグリカン類、催眠剤類、β−アドレナリン作動性拮抗剤類、抗不安剤類、 強カトランキライザー類、抗うつ剤類、ペプチドホルモン類、コルチコールステ ロイド類、タ ンパク同化ステロイド類、エストロゲン類およびプロゲステロン類からなる群か ら選択される請求の範囲18記載の医薬組成物。 22.前記医薬が抗ウイルス剤である請求の範囲21記載の医薬組成物。 23.前記抗ウイルス剤がAZTまたはAZT-CDSである請求の範囲22記載の医薬組成 物。 24.前記医薬が高ウイルス剤である請求の範囲21記載の医薬組成物。 25.前記抗真菌剤がミコナゾールである請求の範囲24記載の医薬組成物。 26.前記抗真菌剤がアムホテリシンBである請求の範囲24記載の医薬組成物。 27.前記医薬が抗てんかん化合物である請求の範囲21記載の医薬組成物。 28.前記抗てんかん化合物がジランチンである請求の範囲27記載の医薬組成物 。 29.前記医薬がβ−アドレナリン作動性拮抗剤である請求の範囲21記載の医薬 組成物。 30.前記のβ−アドレナリン作動性拮抗剤がアダプロロールである請求の範囲 21記載の医薬組成物。 31.前記医薬がタンパク質またはペプチドである請求の範囲18記載の医薬組成 物。 32.前記タンパク質またはペプチドが、カルシトニン、インスリン、黄体形成 ホルモン放出ホルモン(LHRH)またはシクロスポリンである請求の範囲31記載の 医薬組成物。 33.前記投与が非経口経路によって行われる請求の範囲1記載の医薬組成物。 34.前記投与が経口経路によって行われる請求の範囲1記載の医薬組成物。 35.前記投与が直腸経路によって行われる請求の範囲1記載の医薬組成物。 36.前記投与が鼻腔内経路によって行われる請求の範囲1記載の医薬組成物。 37.前記投与が、皮膚への局所塗布によって行われる請求の範囲1記載の医薬 組成物。 38.前記投与が、眼に対する点滴によって行われる請求の範囲1記載の医薬組 成物。 39.前記投与がエアロゾルの吸入によって行われる請求の範囲1記載の医薬組 成物。 40.前記脂質粒子が、リパーゼおよびホスホリパーゼの活性を実質的に含有し ていない請求の範囲1記載の組成物 41.前記脂質粒子がポリマーでコートされている請求の範囲1記載の組成物。 42.前記ポリマーが、ポリラクチド、ポリグリコリド、ポリカプロラクトン、 ゼラチン、アルブミンおよびコラーゲンからなる群から選択される請求の範囲41 記載の組成物。 43.平均直径が約10〜250nmである複数の非細胞性脂質粒子の、医薬として許 容される担体溶液中のナノエマルションを含有する、酸素輸送ペルフルオロカー ボンの非経口投与用医薬組成物であって;前記の各脂質粒子が、バルクで測定し たとき25℃で固相もしくは液晶相である脂質で構成された脂質コアを含有し、前 記脂質コアが、酸素輸送ペルフルオロカーボンを含有しかつリン脂質を含有する 少なくとも一つの表面層で囲まれている医薬組成物。 44.前記ペルフルオロカーボンが、ペルフルオロデカリンまたは ペルフルオロトリブチルアミンである請求の範囲43記載の医薬組成物。 45.ナノエマルションとして投与する医薬を含有する脱水脂質粒子を含有する 医薬組成物であって;前記脂質粒子が、少なくとも一つのリン脂質層によって囲 まれた脂質コアを含有し、前記脂質コアが、バルクで測定したとき25℃で固相も しくは液晶相である脂質で構成されており、そして前記脂質粒子が、再水和され たとき平均直径が約10〜250nmである医薬組成物。 46.さらに凍結保護剤を含有している請求の範囲45記載の組成物。 47.前記凍結保護剤が、グルコース、スクロース、ラクトース、マルトース、 トレハロース、デキストラン、デキストリン、シクロデキストリン、ポリビニル ピロリドンおよびアミノ酸類からなる群から選択される請求の範囲46記載の組成 物。 48.前記凍結保護剤が、脂質に対して0.1〜10重量%の範囲内で存在している 請求の範囲46記載の組成物。 49.前記脂質粒子が医薬を含有している請求の範囲45記載の組成物。 50.前記医薬が、非ステロイドの抗炎症化合物類、抗新生物化合物類、抗生物 質類、抗けいれん剤類、抗てんかん剤類、抗真菌剤類、抗ウイルス剤類、グリコ サミノグリカン類、催眠剤類、β−アドレナリン作動性拮抗剤類、抗不安剤類、 強力トランキライザー類、抗うつ剤類、ペプチドホルモン類、コルチコールステ ロイド類、タンパク同化ステロイド類、エステロゲン類およびプロゲステロン類 からなる群から選択される請求の範囲49記載の組成物。 51.平均直径が約10〜250nmである複数の非細胞性脂質粒子の、眼に適合して いる担体溶液中のナノエマルションを含有する、眼に 対する点滴用医薬組成物であって;前記の各脂質粒子が、バルクで測定したとき 、25℃で固相もしくは液晶相である脂質で構成された脂質コアを含有し、前記脂 質コアがリン脂質を含有する少なくとも一つの表面層によって囲まれている医薬 組成物。 52.前記脂質粒子が眼の中で活性な医薬を含有している請求の範囲51記載の組 成物。 53.前記医薬がβ−遮断剤である請求の範囲52記載の組成物。 54.平均直径が約10〜250nmである複数の非細胞性脂質粒子の、生理的に適合 している担体溶液中のナノエマルションを含有する、生きている組織の生存力を 維持する代用血液であって;前記の各脂質粒子が、バルクで測定したとき25℃で 固相もしくは液晶相である脂質で構成されたコアを含有し、前記脂質コアが、リ ン脂質を含有する少なくとも一つの表面層によって囲まれた酸素輸送ペルフルオ ロカーボンを含有してる代用血液。 55.前記ペルフルオロカーボンがペルフルオロデカリンまたはペルフルオロト リブチルアミンである請求の範囲54記載の組成物。 56.下記ステップ: 0.5:1−1.5:1の重量比の範囲内でリン脂質とトリグリセリドを含有する混 合物を製造し、そして前記トリグリセリドが25℃より高い固相から液相への転移 温度を有し; 前記混合物を、トリグリセリドの固相から液相への転移温度より低い温度で、 水溶液中に懸濁させ;次いで 生成した懸濁液をホモジェナイズして、平均粒径が約10nm〜250nmである脂質 粒子のナノエマルションを得る; ステップを含んでなる、医薬投与用ナノエマルションの製造方法。 57.重量ベースで測定したとき平均直径が50〜250nmである複数 の非細胞性脂質粒子を、医薬として許容される担体溶液中に含有するナノエマル ションを、動物に投与することからなる動物の治療方法であって;前記の各脂質 粒子が、バルクで測定したとき25℃で固相もしくは液晶相である脂質で構成され かつリン脂質を含有する少なくとも一つの表面層で囲まれた脂質コアを含有し、 そして前記脂質粒子が医薬を含有している治療方法。 58.前記脂質粒子の平均直径が20〜180nmの範囲内にある請求の範囲57記載の 方法。 59.医薬が、非ステロイドの抗炎症化合物類、抗新生物化合物類、抗生物質類 、抗けいれん剤類、抗てんかん剤類、抗真菌剤類、抗ウイルス剤類、グリコサミ ノグリカン類、催眠剤類、β−アドレナリン作動性拮抗剤類、抗不安剤類、強カ トランキライザー類、抗うつ剤類、ペプチドホルモン類、コルチコールステロイ ド類、タンパク同化ステロイド類、エステロゲン類およびプロゲステロン類から なる群から選択される請求の範囲57記載の方法。 60.前記ナノエマルションが非経口で投与される請求の範囲57記載の方法。 61.前記ナノエマルションが眼に点滴することによって投与される請求の範囲 57記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/063,613 US5576016A (en) | 1993-05-18 | 1993-05-18 | Solid fat nanoemulsions as drug delivery vehicles |
US063,613 | 1993-05-18 | ||
PCT/US1994/005330 WO1994026252A1 (en) | 1993-05-18 | 1994-05-16 | Solid fat nanoemulsions as drug delivery vehicles |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08511245A true JPH08511245A (ja) | 1996-11-26 |
JP3626184B2 JP3626184B2 (ja) | 2005-03-02 |
Family
ID=22050367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52571694A Expired - Fee Related JP3626184B2 (ja) | 1993-05-18 | 1994-05-16 | 薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体 |
Country Status (10)
Country | Link |
---|---|
US (3) | US5576016A (ja) |
EP (1) | EP0702552B1 (ja) |
JP (1) | JP3626184B2 (ja) |
AT (1) | ATE198040T1 (ja) |
AU (2) | AU676921B2 (ja) |
CA (1) | CA2162993C (ja) |
DE (1) | DE69426418T2 (ja) |
IL (1) | IL109641A (ja) |
SG (1) | SG106029A1 (ja) |
WO (2) | WO1994026252A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002544155A (ja) * | 1999-05-07 | 2002-12-24 | ファルマソル ゲーエムベーハー | 流体および固体脂質の混合物を基礎とする脂質粒子、およびそれらを製造するための方法 |
JP2005500366A (ja) * | 2001-08-03 | 2005-01-06 | 武田薬品工業株式会社 | 安定な乳化組成物 |
JP2009511571A (ja) * | 2005-10-11 | 2009-03-19 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | 経鼻投与用組成物 |
JP2010520304A (ja) * | 2007-03-05 | 2010-06-10 | ワシントン ユニバーシティー | 膜組み込みペプチドのためのナノ粒子輸送システム |
JP2013525385A (ja) * | 2010-04-27 | 2013-06-20 | 重▲慶▼莱美▲薬▼▲業▼股▲分▼有限公司 | ペクチン−アドリアマイシン共役体の凍結乾燥製剤および製造方法 |
JP2014522816A (ja) * | 2011-06-22 | 2014-09-08 | ビョーメ バイオサイエンシズ ピーブイティー.リミテッド | コンジュゲートベースの抗真菌性および抗菌性プロドラッグ |
JP2014530187A (ja) * | 2011-09-16 | 2014-11-17 | 株式会社アモーレパシフィックAmorepacific Corporation | セラミドラメラ構造体及びそれを含む皮膚外用剤組成物 |
CN105408015A (zh) * | 2013-07-25 | 2016-03-16 | 国立科学研究中心 | 多隔室脂质纳米颗粒 |
JP2018530585A (ja) * | 2015-10-16 | 2018-10-18 | マリナス ファーマシューティカルズ インコーポレイテッド | ナノ粒子を含む注射可能な神経ステロイド製剤 |
Families Citing this family (276)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
DE4244122C1 (de) * | 1992-12-24 | 1994-06-01 | Sanol Arznei Schwarz Gmbh | Lyophilisierte, wirkstoffhaltige Emulsion zur intravenösen Applikation |
WO1994023749A1 (en) * | 1993-04-19 | 1994-10-27 | Institute For Advanced Skin Research Inc. | Microemulsion preparation containing difficultly absorbable substance |
ES2070076B1 (es) * | 1993-04-20 | 1996-04-16 | Cusi Lab | Metodo para aumentar la estabilidad de las nanocapsulas durante su almacenamiento. |
US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
IL106578A (en) * | 1993-08-03 | 2000-08-13 | Yissum Res Dev Co | Pharmaceutical compositions for drug targeting |
FR2709666B1 (fr) * | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
US5672358A (en) * | 1994-06-21 | 1997-09-30 | Ascent Pharmaceuticals, Inc. | Controlled release aqueous emulsion |
JPH0827018A (ja) * | 1994-07-22 | 1996-01-30 | Sanwa Kagaku Kenkyusho Co Ltd | 生理活性ペプチド又は蛋白質を含有する薬剤組成物 |
KR19990045763A (ko) * | 1995-09-18 | 1999-06-25 | 유나이티드 스테이트 아미 메디칼 리서치 머티어리얼커맨드 (유에스에이엠알엠씨) | 비공유결합성으로 착염화된 다가의 프로테오좀 서브-유니트 백신의 개선된 제조 방법 |
WO1997015306A1 (en) * | 1995-10-25 | 1997-05-01 | Janssen Pharmaceutica N.V. | Infusions of neuroprotectants and perfluorochemicals |
US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
ES2118033B1 (es) * | 1996-02-16 | 1999-07-01 | Bial Ind Farmaceutica S A | Formulacion farmaceutica antiinflamatoria. |
SE9602280D0 (sv) * | 1996-06-10 | 1996-06-10 | Pharmatrix Ab | Immunstimulerande lipidformulering |
WO1998000110A1 (en) * | 1996-07-03 | 1998-01-08 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
KR100542816B1 (ko) * | 1996-08-22 | 2006-01-11 | 알티피 파마 코포레이션 | 수불용성 물질의 미립자를 포함하는 조성물 및 이것의 제조 방법 |
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
US6071904A (en) * | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
US7060277B2 (en) * | 1996-12-30 | 2006-06-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins |
CA2282411A1 (en) * | 1997-02-27 | 1998-09-03 | Nippon Shinyaku Co., Ltd. | Fat emulsion for oral administration |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US5980912A (en) * | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
SE9702776D0 (sv) * | 1997-07-22 | 1997-07-22 | Pharmacia & Upjohn Ab | Method of preparing pharmaceutical compositions |
US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
US6270464B1 (en) | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
US6221378B1 (en) | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
DE69923300T2 (de) | 1998-03-09 | 2006-01-05 | Takeda Pharmaceutical Co. Ltd. | Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung |
DE19819273A1 (de) * | 1998-04-30 | 1999-11-11 | Pharmatec International S Giul | Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung |
KR100682154B1 (ko) * | 1998-05-07 | 2007-02-12 | 코릭사 코포레이션 | 아쥬번트 조성물 및 그의 사용방법 |
TWI241915B (en) | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
CN1245955C (zh) | 1998-05-29 | 2006-03-22 | 斯凯伊药品加拿大公司 | 热保护微粒组合物及其最终蒸汽灭菌的方法 |
EP1091762A1 (en) * | 1998-07-02 | 2001-04-18 | Genzyme Corporation | Transgene expression in polarized cells |
DE19830375A1 (de) * | 1998-07-08 | 2000-01-13 | K D Pharma Bexbach Gmbh | Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen |
JP2007262088A (ja) * | 1998-08-31 | 2007-10-11 | Nipro Corp | 栄養輸液製剤 |
DE69929128T2 (de) * | 1998-08-31 | 2006-06-29 | Nipro Corp. | Nährstoffinfusionspräparat |
AU6333499A (en) * | 1998-10-14 | 2000-05-01 | Cognis Deutschland Gmbh | Use of nanoscale sterols and sterol esters |
KR20010073232A (ko) | 1998-11-20 | 2001-07-31 | 추후제출 | 분산성 인지질로 안정화된 마이크로입자 |
FR2787326B1 (fr) * | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
CA2358448C (en) * | 1998-12-30 | 2009-02-10 | Dexcel Ltd. | Dispersible concentrate for the delivery of cyclosporin |
US8236335B2 (en) * | 1999-04-28 | 2012-08-07 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US7655252B2 (en) * | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US7767216B2 (en) * | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
AU763945B2 (en) * | 1999-06-04 | 2003-08-07 | Skyepharma Inc. | Oil-core compositions for the sustained release of hydrophobic drugs |
US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
US7919113B2 (en) * | 1999-12-30 | 2011-04-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dispersible concentrate lipospheres for delivery of active agents |
US6541025B1 (en) | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
US6514523B1 (en) | 2000-02-14 | 2003-02-04 | Ottawa Heart Institute Research Corporation | Carrier particles for drug delivery and process for preparation |
AU3847801A (en) * | 2000-02-15 | 2001-08-27 | Intellivax International Inc | Proteosome influenza vaccine |
FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
AU2001245552A1 (en) * | 2000-03-09 | 2001-09-17 | Emory University | Transcutaneous immunization for large particulate antigens |
US6861060B1 (en) | 2000-04-21 | 2005-03-01 | Elena Luriya | Personal care formulations |
DE10027948A1 (de) * | 2000-06-08 | 2001-12-20 | Henkel Kgaa | Verfahren zur Herstellung von Nanopartikel-Suspensionen |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
US8586094B2 (en) | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US7037528B2 (en) * | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
EP2545937A1 (en) * | 2001-06-05 | 2013-01-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
US6676958B2 (en) * | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
WO2003009868A1 (en) * | 2001-07-26 | 2003-02-06 | Otago Innovation Limited | Antigenic compositions |
US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
EP1429749A2 (en) | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
IL145926A0 (en) | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
AU2002353118A1 (en) * | 2001-12-11 | 2003-07-24 | Dor Biopharma, Inc. | Lipid particles and suspensions and uses thereof |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
JP4549625B2 (ja) * | 2002-01-05 | 2010-09-22 | 株式會社アモーレパシフィック | 人参サポニン代謝産物を有効成分とする微細乳化粒子及びその製造方法、並びにこれを含有する皮膚老化防止用の化粧料組成物 |
KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
US6899890B2 (en) * | 2002-03-20 | 2005-05-31 | Kv Pharmaceutical Company | Bioadhesive drug delivery system |
US6824763B2 (en) | 2002-05-30 | 2004-11-30 | Kimberly-Clark Worldwide, Inc. | Anti-fungal powder having enhanced excipient properties |
US8435942B2 (en) * | 2002-05-31 | 2013-05-07 | Transdermal Biotechnology, Inc. | Methods for formulating stabilized insulin compositions |
US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
HUP0202032A2 (hu) * | 2002-06-19 | 2004-10-28 | D. Endre Radics | Nanoemulziós formulációban található bioaktív anyagok emberi szervezetbe való bevitele a szájüreg nyálkahártyáján keresztül, mechanikus pumpájú spray által. |
US20040106785A1 (en) * | 2002-07-25 | 2004-06-03 | Micrologix Biotech Inc. | Inhibitors of RNA dependent RNA polymerase and uses thereof |
US20040213837A1 (en) * | 2002-08-05 | 2004-10-28 | Sankaram Mantripragada | Oil-core compositions for the sustained release of hydrophobic drugs |
EP1553993B1 (en) * | 2002-10-21 | 2016-03-30 | Allvivo, Inc. | Surface coating comprising bioactive compound |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
NZ540166A (en) | 2002-10-25 | 2007-06-29 | Foamix Ltd | Cosmetic and pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
ITMI20022323A1 (it) * | 2002-10-31 | 2004-05-01 | Maria Rosa Gasco | Composizioni farmaceutiche atte al trattamento di malattie oftalmiche. |
US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
ES2376875T3 (es) | 2003-02-14 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo |
WO2004084859A2 (en) * | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
CA2538887A1 (en) * | 2003-09-15 | 2005-03-31 | Id Biomedical Corporation Of Quebec | Measles subunit vaccine |
WO2005030172A1 (en) * | 2003-09-24 | 2005-04-07 | The Regents Of The University And Methods | Antimicrobial nanoemulsion compositions and methods |
EA200600877A1 (ru) * | 2003-10-31 | 2006-12-29 | Тева Фармасьютикал Индастриз, Лтд. | Наночастицы для доставки лекарств |
WO2005077337A2 (en) * | 2004-02-05 | 2005-08-25 | Baxter International Inc. | Dispersions prepared by use of self-stabilizing agents |
ES2387619T3 (es) * | 2004-04-19 | 2012-09-27 | Centre National De La Recherche Scientifique (Cnrs) | Suplementos de tensioactivos pulmonares |
ITMI20041151A1 (it) * | 2004-06-09 | 2004-09-09 | Maria Rosa Gasco | Nanoparticelle lipidiche come agenti veicolanti per acidi nucleici procedimento per la loro preparazione e loro uso |
US7348802B2 (en) * | 2004-06-15 | 2008-03-25 | Stmicroelectronics Pvt. Ltd. | Differential receiver |
KR101347105B1 (ko) | 2004-06-25 | 2014-01-02 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 신경계 장애의 예방을 위한 조성물 및 방법 |
US20060286124A1 (en) * | 2004-06-30 | 2006-12-21 | Id Biomedical Corporation Of Quebec | Vaccine compositions and methods of treating coronavirus infection |
US7871632B2 (en) * | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
US20060057216A1 (en) * | 2004-09-15 | 2006-03-16 | Salamone Joseph C | Low-obscuration image transmitting particulate ocular therapeutic formulations |
EP1674085A1 (en) * | 2004-12-22 | 2006-06-28 | Universite Libre De Bruxelles | Solid lipidic particles as pharmaceutically acceptable fillers or carriers for inhalation |
EP1861067A2 (en) * | 2005-03-09 | 2007-12-05 | Combe Incorporated | Stable mixed emulsions comprising semisolid dispersions of at least two discrete and distinctly different particle size ranges |
FR2885538B1 (fr) * | 2005-05-16 | 2007-08-10 | Univ Claude Bernard Lyon | Nouveau procede de preparation de particules lipidiques solides, mettant en oeuvre un reacteur membranaire |
FR2887457B1 (fr) * | 2005-06-23 | 2007-10-05 | Fond Bettencourt Schueller | Vaccination par ciblage transcutane |
AU2006346369B2 (en) | 2005-07-18 | 2013-02-21 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
US20070065390A1 (en) * | 2005-09-19 | 2007-03-22 | Eric Spengler | Stable emulsion systems with high salt tolerance |
US7638142B2 (en) * | 2005-10-12 | 2009-12-29 | Vitamin Science, Inc. | Therapeutic composition for the treatment of dry eye syndrome |
WO2007054336A1 (de) * | 2005-11-10 | 2007-05-18 | Vortex-Nanofluid Gmbh | Vorrichtung und verfahren zum herstellen von dispersionen |
CA2631927C (en) | 2005-12-01 | 2015-08-18 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
KR100792557B1 (ko) * | 2006-04-05 | 2008-01-09 | 한남대학교 산학협력단 | 나노 캡슐화를 이용하여 제조된 지질 핵 및 고분자 쉘구조를 갖는 단백질 약물 전달용 나노 미립구 |
US10138279B2 (en) | 2006-04-13 | 2018-11-27 | Regents Of The University Of Michigan | Compositions and methods for Bacillus anthracis vaccination |
US9839685B2 (en) * | 2006-04-13 | 2017-12-12 | The Regents Of The University Of Michigan | Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen |
US20080038295A1 (en) * | 2006-04-13 | 2008-02-14 | Regents Of The University Of Michigan | Compositions and methods for orthopox virus vaccination |
US20070243137A1 (en) * | 2006-04-18 | 2007-10-18 | Nanoprobes, Inc. | Cell and sub-cell methods for imaging and therapy |
PL2061427T3 (pl) * | 2006-09-15 | 2011-12-30 | Echo Pharmaceuticals Bv | Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
WO2008140594A2 (en) | 2006-12-01 | 2008-11-20 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
MX2009005727A (es) | 2006-12-01 | 2009-08-27 | Anterios Inc | Nanoparticulas de entidad anfifilica. |
SG178761A1 (en) * | 2007-02-07 | 2012-03-29 | Sigma Tau Ind Farmaceuti | Recombinant antigens of human cytomegalovirus (hcmv) |
EP2142216B1 (en) * | 2007-03-30 | 2015-04-22 | Particle Sciences, Inc. | Particle formulations and uses thereof |
WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
WO2008135855A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
US8309129B2 (en) | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US20080292663A1 (en) * | 2007-05-22 | 2008-11-27 | Gerber Jay D | Adjuvant compositions and methods for delivering vaccines |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
CN101765423B (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
US8974827B2 (en) | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
EP2200613B1 (en) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
WO2009073215A1 (en) | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8063020B2 (en) * | 2007-12-22 | 2011-11-22 | Simpkins Cuthbert O | Resuscitation fluid |
US8618056B2 (en) | 2007-12-22 | 2013-12-31 | Cuthbert O. Simpkins | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
US8906855B2 (en) | 2007-12-22 | 2014-12-09 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
WO2009143175A2 (en) * | 2008-05-19 | 2009-11-26 | Children's Medical Center Corporation | Sensory-specific local anesthesia and prolonged duration local anesthesia |
WO2009143174A2 (en) * | 2008-05-19 | 2009-11-26 | Children's Medical Center Corporation | Chemical permeation enhancers enhance nerve blockade by toxins |
EP2293813A4 (en) | 2008-05-23 | 2012-07-11 | Univ Michigan | NANOEMULSION VACCINES |
US8268796B2 (en) | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
DE102008045152A1 (de) * | 2008-07-09 | 2010-01-14 | Universität Duisburg-Essen | Künstliche Sauerstoffträger und ihre Verwendung |
WO2010009291A1 (en) * | 2008-07-16 | 2010-01-21 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles containing bioactive peptides |
US20100092526A1 (en) | 2008-09-26 | 2010-04-15 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
US8309107B2 (en) * | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
US9974844B2 (en) | 2008-11-17 | 2018-05-22 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
FR2939699B1 (fr) | 2008-12-12 | 2011-05-06 | Univ Angers | Procede de preparation de nanoparticules lipidiques |
CA2749698C (en) * | 2009-01-30 | 2017-08-01 | Cuthbert O. Simpkins | Resuscitation fluid |
US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
CA2756685C (en) * | 2009-04-15 | 2019-12-24 | Oxygen Biotherapeutics, Inc. | Emulsions of perfluorocarbons |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US8668911B2 (en) * | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
CN101579291B (zh) * | 2009-05-20 | 2011-06-15 | 清华大学 | 一种白藜芦醇磷脂复合物纳米乳液及其制备方法与应用 |
EP2442827B1 (en) * | 2009-06-16 | 2016-01-06 | The Regents of the University of Michigan | Nanoemulsion vaccines |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
EP2461813A4 (en) | 2009-08-05 | 2014-02-19 | Univ Wake Forest Health Sciences | COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS IN PROSTATE CANCER CELLS |
BR112012007473A2 (pt) | 2009-10-02 | 2019-05-07 | Foamix Ltd | composições tópicas de tetraciclina e respectivo método de uso |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
WO2011075623A1 (en) * | 2009-12-18 | 2011-06-23 | Latitude Pharmaceuticals, Inc. | One - phase gel compos ition compri s ing phos pholi pids |
FR2956320B1 (fr) * | 2010-02-17 | 2013-12-20 | Commissariat Energie Atomique | Nanoemulsion pour la delivrance d'au moins deux agents d'interet |
US20110229516A1 (en) * | 2010-03-18 | 2011-09-22 | The Clorox Company | Adjuvant phase inversion concentrated nanoemulsion compositions |
PL2550020T3 (pl) | 2010-03-24 | 2015-12-31 | Medesis Pharma | Mikroemulsja odwróconych miceli zawierających jony metali i jej zastosowanie |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
WO2011123479A1 (en) | 2010-03-29 | 2011-10-06 | Academia Sinica | Quantitative measurement of nano / micro particle endocytosis with cell mass spectrometry |
US10758630B2 (en) | 2010-08-13 | 2020-09-01 | The Johns Hopkins University | Topical compositions and methods of detection and treatment |
US8658676B2 (en) * | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
WO2012094541A2 (en) * | 2011-01-05 | 2012-07-12 | The Regents Of The University Of California | Acoustically responsive particles with decreased cavitation threshold |
WO2012125214A1 (en) | 2011-03-17 | 2012-09-20 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
US8883220B2 (en) | 2011-09-16 | 2014-11-11 | Nanocare Technologies, Inc. | Compositions of jasmonate compounds |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
WO2013082503A1 (en) * | 2011-12-01 | 2013-06-06 | Flow Pharma, Inc. | Peptide particle formulation |
CA3170184A1 (en) | 2012-03-12 | 2013-09-19 | Advanced Bioadjuvants, Llc | Adjuvant and vaccine compositions |
TWI483747B (zh) * | 2012-05-29 | 2015-05-11 | Univ Nat Chiao Tung | 口服式藥物載體及其製備方法 |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US20140234433A1 (en) * | 2013-02-15 | 2014-08-21 | Nicholas V. Perricone | Topical Composition for Stimulating Epidermis and Dermis Layers of the Skin |
WO2014130921A1 (en) | 2013-02-25 | 2014-08-28 | Particle Sciences, Inc. | Particle formulations for delivery of tlr agonists and antigens |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
HUE042711T2 (hu) | 2013-03-15 | 2019-07-29 | Childrens Medical Ct Corp | Neosaxitoxin kombinációs készítmények meghosszabbított helyi érzéstelenítésre |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9925149B2 (en) | 2013-10-14 | 2018-03-27 | Nanosphere Health Sciences, Llc | Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers |
KR102427785B1 (ko) | 2013-10-25 | 2022-07-29 | 인스메드 인코포레이티드 | 프로스타사이클린 화합물, 조성물 및 이의 사용 방법 |
MX2016008640A (es) * | 2013-12-31 | 2016-10-07 | Infectious Disease Res Inst | Formulaciones de vacuna de vial unico. |
US9895311B2 (en) * | 2014-09-25 | 2018-02-20 | Pharmiva Ab | Foam-forming compositions and methods for delivering an active to a body cavity |
CA2967385C (en) | 2014-11-18 | 2023-05-16 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
US20160151285A1 (en) * | 2014-11-28 | 2016-06-02 | University Of Malaya | Method to produce slow release delivery carrier lipid nanoparticles of different log p value |
CA3050535C (en) | 2014-12-15 | 2021-11-09 | Richard Clark Kaufman | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals |
EP3240534A4 (en) | 2014-12-31 | 2018-12-19 | Nanocare Technologies, Inc. | Jasmonate derivatives and compositions thereof |
CA2974208A1 (en) * | 2015-01-21 | 2017-04-06 | Michael WILLINSKY | Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler |
CA3089686A1 (en) | 2015-03-10 | 2016-09-15 | Nanosphere Health Sciences, Llc | A nanoparticle drug delivery comprising liquid lipids and cannabinoids encapsulated in a single layer of essential phospholipids |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
CN110381929A (zh) * | 2016-06-13 | 2019-10-25 | 阿森迪亚制药有限责任公司 | 卡维地洛分散系统的肠胃外缓释传递 |
CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
CN110198703A (zh) | 2016-11-21 | 2019-09-03 | 艾里奥治疗公司 | 大试剂的透皮递送 |
CA3053158A1 (en) * | 2017-02-15 | 2018-08-23 | Molecular Infusions, Llc | Formulations |
BR112019024334A2 (pt) | 2017-05-23 | 2020-06-16 | Pharmiva Ab | Composições formadoras de espuma para liberar um ativo para uma cavidade do corpo |
TWI719263B (zh) * | 2017-10-27 | 2021-02-21 | 財團法人國家衛生研究院 | 用於鼻黏膜之奈米級乳液免疫載劑及其製備方法 |
KR102052912B1 (ko) * | 2018-03-30 | 2019-12-06 | 중앙대학교 산학협력단 | 산소를 함유하는 나노 버블의 제조 방법, 나노 버블 및 이를 포함하는 약물 전달체 |
BR112021001345A2 (pt) * | 2018-07-18 | 2021-04-20 | Glatt Gmbh | formulações multiparticuladas de canabinoides |
SG11202106144VA (en) * | 2018-12-11 | 2021-07-29 | Disruption Labs Inc | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
EP3937912A4 (en) * | 2019-03-13 | 2022-12-21 | Ulagaraj Selvaraj | STABILIZED SOLID NANOPARTICLE FORMULATIONS OF CANNABINOIDS AND CANNABINOID ANALOGS WITH REDUCED OSTWALD RIPENING FOR ORAL, INHALATION, NASAL AND PARENTERAL DRUG DELIVERY |
TR201905678A2 (tr) * | 2019-04-16 | 2020-11-23 | Istanbul Medipol Ueniversitesi | Kurkumi̇n ve pi̇peri̇n doğal bi̇leşenleri̇ni̇ i̇hti̇va eden kati li̇pi̇t emulsi̇yonlarinin tedavi̇ amaçli uygulamalari |
US11458098B2 (en) | 2019-04-29 | 2022-10-04 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
US20200352191A1 (en) * | 2019-05-06 | 2020-11-12 | Karl Lonsbery | Edible formulations and uses thereof |
EP4084658A4 (en) * | 2020-01-02 | 2024-01-17 | Spoke Sciences Inc | SYSTEMS AND METHODS FOR PRODUCING HOMOGENEOUS MIXTURES OF BREWED DRINKS AND ACTIVE INGREDIENTS |
WO2022026796A1 (en) * | 2020-07-31 | 2022-02-03 | Altaire Pharmaceuticals, Inc. | Ophthalmic compositions for delivering meibum-like materials |
US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
WO2023108513A1 (zh) * | 2021-12-16 | 2023-06-22 | 威海天原生物科技有限公司 | 植物油制剂及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US5023271A (en) * | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
IL88076A (en) * | 1987-10-28 | 1993-01-14 | Nippon Shinyaku Co Ltd | Fat emulsions as drug carriers |
US5171737A (en) * | 1989-03-03 | 1992-12-15 | The Liposome Company, Inc. | Emulsions |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
WO1991007171A1 (en) * | 1989-11-13 | 1991-05-30 | Nova Pharmaceutical Corporation | Lipospheres for controlled delivery of substances |
FR2660193B1 (fr) * | 1990-04-03 | 1994-11-04 | Philippe Maincent | Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules. |
US5306508A (en) * | 1990-06-22 | 1994-04-26 | The Regents Of The University Of California | Red blood cell surrogate |
AU658608B2 (en) * | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
US5284663A (en) * | 1991-07-23 | 1994-02-08 | Temple University | Salt film encapsulated perfluorocarbons |
DE4131562A1 (de) * | 1991-09-18 | 1993-03-25 | Medac Klinische Spezialpraep | Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln) |
CA2130357A1 (en) * | 1992-02-18 | 1993-08-19 | Doron Friedman | Dry compositions for preparing submicron emulsions |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
-
1993
- 1993-05-18 US US08/063,613 patent/US5576016A/en not_active Expired - Lifetime
-
1994
- 1994-05-12 IL IL10964194A patent/IL109641A/xx not_active IP Right Cessation
- 1994-05-16 CA CA002162993A patent/CA2162993C/en not_active Expired - Fee Related
- 1994-05-16 SG SG9604518A patent/SG106029A1/en unknown
- 1994-05-16 AU AU69480/94A patent/AU676921B2/en not_active Ceased
- 1994-05-16 WO PCT/US1994/005330 patent/WO1994026252A1/en active IP Right Grant
- 1994-05-16 JP JP52571694A patent/JP3626184B2/ja not_active Expired - Fee Related
- 1994-05-16 EP EP94917967A patent/EP0702552B1/en not_active Expired - Lifetime
- 1994-05-16 DE DE69426418T patent/DE69426418T2/de not_active Expired - Fee Related
- 1994-05-16 AT AT94917967T patent/ATE198040T1/de not_active IP Right Cessation
- 1994-05-18 AU AU69164/94A patent/AU6916494A/en not_active Abandoned
- 1994-05-18 US US08/553,350 patent/US5716637A/en not_active Expired - Fee Related
- 1994-05-18 WO PCT/US1994/005589 patent/WO1994026255A1/en active Application Filing
-
1996
- 1996-08-27 US US08/697,704 patent/US5662932A/en not_active Expired - Lifetime
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002544155A (ja) * | 1999-05-07 | 2002-12-24 | ファルマソル ゲーエムベーハー | 流体および固体脂質の混合物を基礎とする脂質粒子、およびそれらを製造するための方法 |
JP2005500366A (ja) * | 2001-08-03 | 2005-01-06 | 武田薬品工業株式会社 | 安定な乳化組成物 |
JP2009511571A (ja) * | 2005-10-11 | 2009-03-19 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | 経鼻投与用組成物 |
JP2010520304A (ja) * | 2007-03-05 | 2010-06-10 | ワシントン ユニバーシティー | 膜組み込みペプチドのためのナノ粒子輸送システム |
US8496945B2 (en) | 2007-03-05 | 2013-07-30 | Washington University | Nanoparticle delivery systems for membrane-integrating peptides |
JP2013525385A (ja) * | 2010-04-27 | 2013-06-20 | 重▲慶▼莱美▲薬▼▲業▼股▲分▼有限公司 | ペクチン−アドリアマイシン共役体の凍結乾燥製剤および製造方法 |
JP2014522816A (ja) * | 2011-06-22 | 2014-09-08 | ビョーメ バイオサイエンシズ ピーブイティー.リミテッド | コンジュゲートベースの抗真菌性および抗菌性プロドラッグ |
JP2014530187A (ja) * | 2011-09-16 | 2014-11-17 | 株式会社アモーレパシフィックAmorepacific Corporation | セラミドラメラ構造体及びそれを含む皮膚外用剤組成物 |
CN105408015A (zh) * | 2013-07-25 | 2016-03-16 | 国立科学研究中心 | 多隔室脂质纳米颗粒 |
JP2016525143A (ja) * | 2013-07-25 | 2016-08-22 | センター ナショナル デ ラ レシェルシェ サイエンティフィック(シーエヌアールエス)Centre National De La Recherche Scientifique(Cnrs) | マルチコンパートメント脂質ナノ粒子 |
JP2018530585A (ja) * | 2015-10-16 | 2018-10-18 | マリナス ファーマシューティカルズ インコーポレイテッド | ナノ粒子を含む注射可能な神経ステロイド製剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2162993C (en) | 2004-03-30 |
JP3626184B2 (ja) | 2005-03-02 |
EP0702552A1 (en) | 1996-03-27 |
DE69426418D1 (de) | 2001-01-18 |
EP0702552B1 (en) | 2000-12-13 |
EP0702552A4 (en) | 1997-05-21 |
AU6948094A (en) | 1994-12-12 |
DE69426418T2 (de) | 2001-05-10 |
AU6916494A (en) | 1994-12-12 |
ATE198040T1 (de) | 2000-12-15 |
SG106029A1 (en) | 2004-09-30 |
WO1994026255A1 (en) | 1994-11-24 |
US5576016A (en) | 1996-11-19 |
IL109641A0 (en) | 1994-08-26 |
CA2162993A1 (en) | 1994-11-24 |
WO1994026252A1 (en) | 1994-11-24 |
US5716637A (en) | 1998-02-10 |
IL109641A (en) | 2000-02-29 |
AU676921B2 (en) | 1997-03-27 |
US5662932A (en) | 1997-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3626184B2 (ja) | 薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体 | |
KR0159114B1 (ko) | 인지질이 피복된 미세결정성 수불용성 약제의 주사형 제제 | |
AU684460B2 (en) | Topical and transdermal delivery system utilizing submicron oil spheres | |
JP4212113B2 (ja) | サイクロスポリン乳剤 | |
US5665379A (en) | Lipid particle forming matrix, preparation and use thereof | |
JP2001508445A (ja) | 溶解性に劣る薬物のためのエマルジョンビヒクル | |
AU763945B2 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
KR100446832B1 (ko) | 장벽을 통한 활성성분의 비침습성 도포 또는 운반용 제제를 제조하기 위한 액체 소적 | |
JPH0798740B2 (ja) | 薬物担体 | |
EP0799035B1 (en) | Emulsion suitable for administering a sphingolipid and use thereof | |
JPH03176425A (ja) | 脂肪乳剤 | |
JP2653245B2 (ja) | 脂肪乳剤 | |
US20040213837A1 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
KR100812764B1 (ko) | 구조화된 암포테리신 b 유제 | |
JP4719355B2 (ja) | パルトリシン誘導体の注射可能な薬学的処方物 | |
JP3074732B2 (ja) | 脂肪乳剤 | |
JP2022514991A (ja) | 安定な麻酔薬製剤および関連する剤形 | |
AU2001280084A1 (en) | Amphotericin B structured emulsion | |
JPH1160491A (ja) | アムホテリシンb含有製剤 | |
JPH0489430A (ja) | 低血圧維持剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041102 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041202 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081210 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091210 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101210 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111210 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |